Angele Maki

Angele Maki has a strong background in business development and corporate strategy in the biotechnology and pharmaceutical industries. Angele is currently serving as the Chief Business Officer at Hummingbird Bioscience and is a Leadership Team/Director/Board Member at Canadian Entrepreneurs in Life Science (CELS). Angele has also worked as an Advisor at Pear VC and Paradox Immunotherapeutics. In their previous roles, they held positions such as Senior Vice President and Head of Business Development at ReCode Therapeutics, Vice President of Venture Science and Corporate Business Development at Eli Lilly and Company, and Executive Director of Business Development and Licensing at Merck. Angele has extensive experience in leading strategic transactions, executing partnerships, and evaluating and in-licensing technologies to drive pipeline growth. Angele has been involved in notable deals with companies such as Genentech, Bristol Myers Squibb, and Lycia Therapeutics.

Angele Maki holds a PhD in Biological Chemistry from Stanford University. Angele pursued a postdoc in Molecular Biology at Scripps Research. Angele obtained a B.Sc. in Chemistry from The University of Winnipeg.